News | Embolic Protection Devices | April 11, 2017

PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device

Pennsylvania hospital system is one of 27 worldwide testing device meant to reduce stroke risk during TAVR

PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device

April 11, 2017 — Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device designed to reduce risk of stroke during transcatheter aortic valve replacement (TAVR).

Aortic stenosis is one of the most common and most serious heart valve diseases. Left untreated, aortic stenosis gradually diminishes quality of life and leads to heart failure and death. The gold standard for treating aortic stenosis has been surgical aortic valve replacement; however, changes in cardiovascular medicine have led to the minimally invasive, catheter-based TAVR procedure for patients deemed too high risk for surgery. Patients having either type of aortic valve replacement are at risk of brain injury that may range from memory loss and speech challenges to debilitating strokes.

The international clinical trial, called REFLECT, studies the safety and efficacy of the Keystone Heart TriGuard cerebral embolic protection device to minimize the risk of cerebral damage during TAVR and other cardiovascular procedures. TriGuard is designed to reduce the amount of embolic debris from traveling through the blood stream to the brain for patients undergoing TAVR. If this debris travels through the blood stream to the brain, it could possibly cause damage that may lead to a stroke or neurocognitive dysfunction, such as memory loss and speech challenges.

"As physicians, we see firsthand the debilitating effects of brain injury following TAVR can have on our patients," stated Mubashir Mumtaz, M.D., FACS, FACC, chief of cardiothoracic surgery, surgical director of structural heart and principal investigator for the trial at PinnacleHealth. "PinnacleHealth CardioVascular Institute is honored to be selected for this elite global trial, studying a major patient safety initiative."

"This device presents the opportunity to minimize brain injury following TAVR and supports our goal to preserve quality of life," stated Hemal Gada, M.D., MBA, interventional cardiologist and medical director of structural heart at PinnacleHealth.

The TriGuard device is shaped to accommodate anatomic variations of the aortic arch in order to provide full coverage to all brain territories.  It is placed via one of the femoral artery access ports typically used in TAVR, thereby eliminating the need for a third puncture site. 

PinnacleHealth is one of 27 hospital systems in the world, and the only hospital in Pennsylvania, enrolling patients in this trial.

Read the article from TCT 2016 “Delirium Significantly Associated With Brain Lesions in Patients Post-TAVR.”

For more information: www.keystoneheart.com

Related Content

New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
Feature | Inventory Management| April 28, 2017 | Dave Fornell
Tracking cardiovascular device inventory in cath labs, electrophysiology (EP) labs and operating rooms (ORs) can be a
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock
Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
New Hampshire Hospital Expands Vascular Care with Toshiba Medical's Infinix-I Sky +
News | Angiography| April 27, 2017
Wentworth-Douglass Hospital in Dover, N.H., installed Toshiba Medical’s Infinix-i Sky + angiography system in its...
Mercator MedSystems Announces First Enrollment in TANGO Trial for Below-the-Knee Vascular Disease
News | Peripheral Arterial Disease (PAD)| April 27, 2017
Mercator MedSystems Inc. announced the first patient enrollment into the TANGO (Temsirolimus Adventitial Delivery to...
News | Venous Therapies| April 26, 2017
A new Varicose Vein Registry has begun producing useful outcomes information, as reported in the May edition of the...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
Body Weight Fluctuations Linked to More Deaths in People with Coronary Artery Disease
News | Cardiac Diagnostics| April 25, 2017
Repeated cycles of weight loss and gain may be linked to higher risk for stroke, heart attack and death in people with...
Overlay Init